AI-powered image analysis platform for early risk assessment of breast cancer patients
CompanyOwkin, Boston, USA
The company Owkin has developed the AI-supported image analysis platform RlapsRisk® BC for an early assessment of the risk of recurrence in breast cancer patients. The method is suitable for adults who have been diagnosed with primary invasive breast cancer (ER+/HER2-). To assess the risk, surgically removed patient tumor tissue samples are examined on digitized slides. Artificial intelligence analyses patterns and characteristics of the tumor and compares them with a clinical data set that includes data from 1,800 breast cancer patients (including 1,480 HER2-/HR+). A machine learning system automatically integrates new insights, meaning the platform is in continuous training to improve the accuracy of its predictions. So far it has been shown that the platform has a cumulative sensitivity of 76% and therefore correctly diagnoses more high-risk patients as positive than the clinical score. After five years, the diagnostic procedure achieved a dynamic specificity of 76%. In summary, the RlapsRisk® BC platform can help doctors better assess the risk of their patients in order to decide on an appropriate form of therapy as early as possible. Furthermore, the researchers hope that the method will provide new insights and an improved understanding of the mechanisms of highly aggressive tumors in the future.
RlapsRisk® BC. Assess the risk of breast cancer relapse.
www.owkin.com
Added on: 01-18-2024
[1] https://www.owkin.com/rlapsrisk-bc
